The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics announced that its Chief Technology Officer, Ben Beneski, will participate in a panel discussion focused on advancing next-generation cell-based therapies.
The event, hosted by Cancer Research and tagged #FriendsCGT26, will cover recent developments and outlooks in the allogeneic and cell therapy space. Beneski’s involvement underscores the company’s commitment to fostering innovation in cutting-edge treatments. Additional details and registration are available on the official event page.
View post on X Loading...
Earlier this year, Allogene’s vice president Daniel Hunt took part in FiercePharmaEngage to discuss mergers and acquisitions in allogeneic CAR T therapies. The company also recently launched ALLO-329, a new allogeneic CAR-T treatment targeting autoimmune diseases. These initiatives highlight Allogene’s activity in both the business development and research fronts of cell therapy.